Esperion Therapeutics Inc (0ET.SG)
| Previous close | 2.6330 |
| Open | 2.7020 |
| Bid | 2.7690 x 150000 |
| Ask | 2.9400 x 150000 |
| Day's range | 2.7020 - 2.7020 |
| 52-week range | 0.6660 - 3.3270 |
| Volume | |
| Avg. volume | 889 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m. ET. Goldman Sachs Healthcare Conference in Miami Beach on June 12, 2024, at 8:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperi
- GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Levels – – This Makes Bempedoic Acid the First and Only LDL-C Lowering Treatment Indicated for Primary and Secondary Prevention of Cardiovascular Events – – Up To 80% Of Patients Do Not Reach Guideline-Recommended L
- GlobeNewswire
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan. Bempedoic acid, created by Esperion Therapeuti
